Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Letting cancer patients choose their Quit-Smoking method may boost success

NCT ID NCT04634071

Disease control Sponsor: Joseph Valentino, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether letting cancer patients choose their own smoking cessation treatment helps them quit. 126 patients with tobacco-related cancers received either varenicline, bupropion, or nicotine patches based on their preference, plus counseling. The goal was to see if personalized choice improves quit rates compared to randomly assigned treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Varenicline, Bupropion, or nicotine patches
What this could lead to
If successful, this could show that letting cancer patients choose their own smoking cessation method helps them quit more effectively, potentially improving cancer treatment outcomes.
What could go wrong
This is a Phase 2 trial with only 126 participants, so results may not apply to all patients. Quitting smoking is difficult, and the study compares preferences, not a new drug, so the impact may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

126 people

The number who actually took part.

Started

Jan 2021

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * newly diagnosed or recurrent tobacco related malignancy * smoked at least 1 cigarette within 4 weeks of study enrollment * 10-pack year history of cigarette smoking * smoked at least 1 cigarette within 1 month of cancer diagnosis * life expectancy greater than 1 year Exclusion Criteria: * allergy to buproprion, varenicline and transdermal medicine * history of suicide attempt * hospitalized for psychiatric illness within past 2 years * history of active or uncontrolled eating disorder * uncontrolled epilepsy or seizure disorder * pregnant or lactating * within 3 months of myocardial infarction * unstable angina * uncontrolled hypertension * serious arrhythmia * history of taking varenicline or buproprion within one month of enrollment * concurrent enrollment in tobacco cessation therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer, treatment-related are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior, Addictive Neoplasms, Second Primary secondary malignant neoplasm Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer, treatment-related Smoking cessation

Contacts and locations

Locations

  • Med Center Health

    Bowling Green, Kentucky, 42101, United States

  • Owensboro Health Mitchell Memorial Cancer Center

    Owensboro, Kentucky, 42303, United States

  • University Of Kentucky, Markey Cancer Center

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.